W. de Villiers

Fontolizumab in moderate to severe Crohn's disease: A phase 2, randomized, double‐blind, placebo‐controlled, multiple‐dose study

P. Rutgeerts, D. Hommes, C. Bernstein, 2010, Inflammatory bowel diseases.

Fontolizumab in moderate to severe Crohn's disease: A phase 2, randomized, double‐blind, placebo‐controlled, multiple‐dose study

P. Rutgeerts, D. Hommes, C. Bernstein, 2010, Inflammatory bowel diseases.